Peter A Kouides

List of Publications by Year
in descending order

112	2,403	201674	243625
papers	citations	27 h-index	44 g-index

118	118	118	1772
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Examining international practices in the management of pregnant women with von Willebrand disease. Journal of Thrombosis and Haemostasis, 2022, 20, 82-91.	3.8	7
2	Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. Blood Advances, 2022, 6, 228-237.	5.2	15
3	Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. Blood Advances, 2022, 6, 420-428.	5.2	4
4	Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. Blood Advances, 2022, 6, 121-128.	5.2	7
5	Outcomes of longâ€term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review. Haemophilia, 2022, 28, 373-387.	2.1	5
6	All catastrophes are not catastrophic antiphospholipid syndrome. American Journal of Hematology, 2022, 97, 968-974.	4.1	0
7	Impact of obesity on factor VIII and von Willebrand factor levels in patients with Type 1 von Willebrand disease and low von Willebrand factor: An analysis of the ATHNdataset. Haemophilia, 2022, 28, 109-116.	2.1	0
8	Does a Bleeding Disorder Lessen the Efficacy of the 52-mg Levonorgestrel-Releasing Intrauterine System for Heavy Menstrual Bleeding in Adolescents? A Retrospective Multicenter Study. Journal of Adolescent Health, 2022, 71, 204-209.	2.5	2
9	North American Physician Practice Patterns in the Management of Anticoagulation in Pregnancy. Journal of Women's Health, 2021, 30, 829-836.	3.3	3
10	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances, 2021, 5, 301-325.	5.2	152
11	Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia, 2021, 27, 445-453.	2.1	13
12	Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis. Cureus, 2021, 13, e14572.	0.5	3
13	A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 1883-1887.	3.8	59
14	Low von Willebrand Factor in Children and Adolescents. JAMA Pediatrics, 2021, 175, 1060-1067.	6.2	1
15	Primary thromboprophylaxis in a patient with type 3 von Willebrand disease and severe COVIDâ€19 infection. Haemophilia, 2021, 27, e517-e519.	2.1	1
16	von Willebrand disease: proposing definitions for future research. Blood Advances, 2021, 5, 565-569.	5.2	5
17	The Von Willebrand Disease Aging and Bleeding Correlation (VWD ABC) Study. Blood, 2021, 138, 1044-1044.	1.4	0
18	ASXL1 Mutation Is a Novel Risk Factor for Bleeding in Patients with Philadelphia-Negative Myeloproliferative Neoplasms (MPN). Blood, 2021, 138, 3637-3637.	1.4	1

#	Article	IF	Citations
19	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
20	Prospective evaluation of ISTHâ€BAT as a predictor of bleeding disorder in adolescents presenting with heavy menstrual bleeding in a multidisciplinary hematology clinic. Journal of Thrombosis and Haemostasis, 2020, 18, 2542-2550.	3.8	21
21	The spectrum and severity of bleeding in adolescents with low von Willebrand factorâ€"associated heavy menstrual bleeding. Blood Advances, 2020, 4, 3209-3216.	5.2	17
22	Efficacy and safety of halfâ€dose desmopressin for bleeding prophylaxis in bleeding disorder patients undergoing predominantly low to moderate risk invasive procedures. American Journal of Hematology, 2020, 95, E285.	4.1	4
23	Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARSâ€CoVâ€2 infection. Journal of Thrombosis and Haemostasis, 2020, 18, 2640-2645.	3.8	26
24	Effectiveness of intravenous immunoglobulin use in heparin-induced thrombocytopenia. Blood Coagulation and Fibrinolysis, 2020, 31, 287-292.	1.0	8
25	The impact of extended halfâ€life factor concentrates on prophylaxis for severe hemophilia in the United States. American Journal of Hematology, 2020, 95, 960-965.	4.1	19
26	Laboratory misdiagnosis of von Willebrand disease in <scp>postâ€menarchal</scp> females: A <scp>multiâ€center</scp> study. American Journal of Hematology, 2020, 95, 1022-1029.	4.1	15
27	Bleeding disorders in adolescents with heavy menstrual bleeding in a multicenter prospective US cohort. Haematologica, 2020, 105, 1969-1976.	3.5	37
28	Venous Thromboembolism in COVID-19: Towards an Ideal Approach to Thromboprophylaxis, Screening, and Treatment. Current Cardiology Reports, 2020, 22, 52.	2.9	47
29	A Morphometric Analysis of Platelet Dense Granules of Patients with Unexplained Bleeding: A New Entity of Delta-Microgranular Storage Pool Deficiency. Journal of Clinical Medicine, 2020, 9, 1734.	2.4	14
30	A presumed case of Darbepoetinâ€induced myocardial infarction in the patient with MDSâ€RARS. Clinical Case Reports (discontinued), 2020, 8, 658-660.	0.5	1
31	The Prevalence and Impact of Arrhythmias in Hospitalized Patients with Sickle Cell Disorders: A Large Database Analysis. Blood, 2020, 136, 5-6.	1.4	1
32	Bleeding Disorders in Pregnancy. , 2020, , 319-322.		0
33	Design of the Von Willebrand Factor in Pregnancy (VIP) Study. Blood, 2020, 136, 29-29.	1.4	2
34	Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders and Tendencies: Methodology for Delphi Consensus Recommendations. Blood, 2020, 136, 29-29.	1.4	0
35	The Certainty of a Post-Bone Marrow Diagnosis: A Study of the Yield of Bone Marrow Biopsies in a Community Hospital Setting. Blood, 2020, 136, 34-35.	1.4	0
36	Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor. Blood Reviews, 2019, 38, 100572.	5.7	29

#	Article	IF	Citations
37	Regional variation and cost implications of prescribed extended halfâ€life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia, 2019, 25, 668-675.	2.1	38
38	Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Advances, 2019, 3, 2381-2387.	5.2	38
39	Association of Obesity on Laboratory Profiles of Individuals with Type 1 Von Willebrand Disease and Low VWF in the Athn Dataset. Blood, 2019, 134, 2415-2415.	1.4	0
40	Congenital FVIII/IX or VWF Deficiency Does Confer a Lower Rate of Myocardial Infarction-Related Mortality Despite Decreased Cardiovascular Interventions. Blood, 2019, 134, 1120-1120.	1.4	0
41	Cardiac ALL: Most Unusual Occurrence of Lenalidomide-associated Acute Lymphoblastic Leukemia with Subsequent Cardiac Involvement. Cureus, 2019, 11, e6009.	0.5	3
42	Outgrowing the laboratory diagnosis of type 1 von <scp>W</scp>illebrand disease: A two decade study. American Journal of Hematology, 2018, 93, 232-237.	4.1	17
43	A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Advances, 2018, 2, 1325-1333.	5.2	43
44	Feasibility of the Von Willebrand disease PREVENT trial. Thrombosis Research, 2017, 156, 8-13.	1.7	9
45	Safety of a pasteurized plasmaâ€derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data. Transfusion, 2017, 57, 2390-2403.	1.6	13
46	The scope and value of an anticoagulation stewardship program at a community teaching hospital. Journal of Thrombosis and Thrombolysis, 2017, 43, 380-386.	2.1	22
47	Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations. Blood Advances, 2017, 1, 699-702.	5.2	7
48	Validation Study of the Composite Score to Identify Von Willebrand Disease in Children. Journal of Pediatric Hematology/Oncology, 2016, 38, 139-142.	0.6	11
49	Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood, 2015, 126, 2038-2046.	1.4	126
50	Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy. Blood Coagulation and Fibrinolysis, 2015, 26, 383-388.	1.0	46
51	An update on the management of bleeding disorders during pregnancy. Current Opinion in Hematology, 2015, 22, 397-405.	2.5	13
52	Features of Electronic Health Records Necessary for the Delivery of Optimized Anticoagulant Therapy. Annals of Pharmacotherapy, 2015, 49, 113-124.	1.9	12
53	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood, 2015, 126, 761-761.	1.4	2
54	Pharmacokinetics of a Recombinant Von Willebrand Factor in Patients with Severe Von Willebrand Disease. Blood, 2015, 126, 2293-2293.	1.4	0

#	Article	IF	Citations
55	Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. Transfusion, 2014, 54, 1756-1768.	1.6	167
56	Safe and Effective Use of Chronic Transdermal Estradiol for Life-Threatening Uremic Bleeding in a Patient with Coronary Artery Disease. Nephron Extra, 2014, 4, 134-137.	1.1	3
57	A Cross-Sectional Analysis of Cardiovascular Disease in the Hemophilia Population. Blood, 2014, 124, 2836-2836.	1.4	4
58	A Threshold Optical Density Value In Immunoassay Predicts Thrombosis In Patients with Heparin Induced Thrombocytopenia. Blood, 2013, 122, 4755-4755.	1.4	2
59	Validation Study Of The Composite Score To Identify Von Willebrand Disease in Children. Blood, 2013, 122, 2356-2356.	1.4	0
60	Rare case of hemolytic uremic syndrome associated with only one transient low platelet count. Journal of Hematopathology, 2012, 5, 325-327.	0.4	0
61	Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 158, 124-134.	1.1	108
62	von Willebrand Disease in the Pediatric and Adolescent Population. Journal of Pediatric and Adolescent Gynecology, 2010, 23, S3-S10.	0.7	28
63	Predictors of Von Willebrand Disease In Children: A Case-Control Study. Blood, 2010, 116, 712-712.	1.4	0
64	Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. British Journal of Haematology, 2009, 145, 212-220.	2.5	117
65	Effect of SSRI Use On Platelet Function Testing and Bleeding Symptoms.. Blood, 2009, 114, 3508-3508.	1.4	1
66	A Benefit-Risk Review of Systemic Haemostatic Agents. Drug Safety, 2008, 31, 217-230.	3.2	29
67	A Benefit-Risk Review of Systemic Haemostatic Agents. Drug Safety, 2008, 31, 275-282.	3.2	33
68	Bleeding symptom assessment and hemostasis evaluation of menorrhagia. Current Opinion in Hematology, 2008, 15, 465-472.	2.5	17
69	Pathology of Thrombotic Thrombocytopenic Purpura in the Placenta, with Emphasis on the â€œSnowman Signâ€• Pediatric and Developmental Pathology, 2007, 10, 455-462.	1.0	11
70	Platelet function testing: state of the art. Expert Review of Cardiovascular Therapy, 2007, 5, 955-967.	1.5	12
71	Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy. Leukemia and Lymphoma, 2007, 48, 1410-1413.	1.3	48
72	A Multi-Site, Prospective Cross-Over Study of Intranasal Desmopressin and Oral Tranexamic Acid in Women with Menorrhagia and Abnormal Laboratory Hemostasis.. Blood, 2007, 110, 711-711.	1.4	4

#	Article	IF	Citations
73	Systemic Mastocytosis: A Concise Clinical and Laboratory Review. Archives of Pathology and Laboratory Medicine, 2007, 131, 784-791.	2.5	49
74	Females with Severe or Moderate Hemophilia A or B: A U.S. Study.. Blood, 2007, 110, 2146-2146.	1.4	1
75	Rituximab-Induced Leukocytoclastic Vasculitis: A Case Report. Archives of Dermatology, 2006, 142, 246.	1.4	43
76	Aspects of the Laboratory Identification of von Willebrand Disease in Women. Seminars in Thrombosis and Hemostasis, 2006, 32, 480-484.	2.7	21
77	Von Willebrand Disease and other Disorders of Hemostasis in the Patient with Menorrhagia. Women's Health, 2005, 1, 231-244.	1.5	2
78	Disorders of hemostasis and excessive menstrual bleeding: prevalence and clinical impact. Fertility and Sterility, 2005, 84, 1338-1344.	1.0	53
79	Management of excessive menstrual bleeding in women with hemostatic disorders. Fertility and Sterility, 2005, 84, 1352-1359.	1.0	51
80	Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertility and Sterility, 2005, 84, 1345-1351.	1.0	81
81	Diagnosis and management of heparin-induced thrombocytopenia. Expert Review of Cardiovascular Therapy, 2005, 3, 335-345.	1.5	1
82	Near-fatal uterine hemorrhage during induction chemotherapy for acute myeloid leukemia: A case report of bilateral uterine artery embolization. American Journal of Hematology, 2004, 77, 151-155.	4.1	20
83	VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naiî¨ve Multiple Myeloma (MM).. Blood, 2004, 104, 3463-3463.	1.4	14
84	The Variable Success of Managing Bleeding Disorder Related Menorrhagia: A Multicenter Study within the Hemophilia Treatment Center Network.. Blood, 2004, 104, 3089-3089.	1.4	0
85	Viral Safety of Plasma Products. Laboratory Medicine, 2003, 34, 667-671.	1.2	0
86	Metachronous Development of Nonamyloidogenic Î» Light Chain Deposition Disease and IgG Heavy Chain Amyloidosis in the Same Patient. American Journal of Surgical Pathology, 2003, 27, 1477-1482.	3.7	26
87	Evaluation of abnormal bleeding in women. Psychophysiology, 2002, 1, 11-8.	1.1	6
88	Obstetric and gynaecological aspects of von Willebrand disease. Best Practice and Research in Clinical Haematology, 2001, 14, 381-399.	1.7	217
89	Hematologic neoplasia and the central nervous system. , 1999, 62, 234-238.		23
90	Infections affecting blood cell morphology. , 1998, 59, 238-241.		0

#	Article	IF	Citations
91	Understanding the Myelodysplastic Syndromes. Oncologist, 1997, 2, 389-401.	3.7	38
92	Allergic reactions to cyclophosphamide: Delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients. Journal of Allergy and Clinical Immunology, 1996, 97, 26-33.	2.9	37
93	Flutamideâ€induced cyanosis refractory to methylene blue therapy. British Journal of Haematology, 1996, 94, 73-75.	2.5	18
94	Transformation of chronic myelomonocytic leukemia to acute lymphoblastic leukemia: Case report and review of the literature of lymphoblastic transformation of myelodysplastic syndrome. American Journal of Hematology, 1995, 49, 157-162.	4.1	37
95	Large granular lymphocyte leukemia presenting with both amegakaryocytic thrombocytopenic purpura and pure red cell aplasia: Clinical course and response to immunosuppressive therapy. American Journal of Hematology, 1995, 49, 232-236.	4.1	27
96	Pseudoleukemia following the use of G-CSF. American Journal of Hematology, 1995, 49, 258-259.	4.1	14
97	Cytarabine-induced pericarditis: A case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leukemia Research, 1995, 19, 141-144.	0.8	45
98	A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis. Leukemia Research, 1995, 19, 763-770.	0.8	11
99	PNEUMOCYSTIS CARINII PNEUMONIA AS A COMPLICATION OF DESFERRIOXAMINE THERAPY. British Journal of Haematology, 1988, 70, 383-384.	2.5	17
100	Antenatal Diagnosis. , 0, , 99-123.		2
101	Advocacy for Women with Bleeding Disorders. , 0, , 176-183.		1
102	Genetic and Laboratory Diagnosis. , 0, , 90-98.		2
103	Rare Bleeding Disorders. , 0, , 54-64.		0
104	Analgesia and Anesthesia for Pregnant Women with Inherited Bleeding Disorders. , 0, , 151-162.		1
105	Appendix i: Bleeding Score with Assigned Score for Each Bleeding Symptom. , 0, , 184-185.		1
106	Appendix ii: Pictorial Blood Assessment Chart. , 0, , 186-187.		0
107	The newborn. , 0, , 163-175.		0
108	Physiology of Menstruation and Menorrhagia. , 0, , 12-33.		0

#	Article	IF	Citations
109	Obstetric Management. , 0, , 124-150.		2
110	Approach to the Patient with an Inherited Bleeding Disorder. , 0, , 1-11.		1
111	von Willebrand Disease. , 0, , 42-53.		0
112	Hemophilia A and Hemophilia B. , 0, , 34-41.		0